Factors Likely to Have Influenced Earnings Results Actinium Pharmaceuticals (NYSE:ATNM)

0
374

Earnings results for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals, Inc. is estimated to report earnings on 12/15/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.46. The reported EPS for the same quarter last year was $-1.2.

Analyst Opinion on Actinium Pharmaceuticals (NYSE:ATNM)

3 Wall Street analysts have issued ratings and price targets for Actinium Pharmaceuticals in the last 12 months. Their average twelve-month price target is $45.00, predicting that the stock has a possible upside of 283.30%. The high price target for ATNM is $65.00 and the low price target for ATNM is $25.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Actinium Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $45.00, Actinium Pharmaceuticals has a forecasted upside of 283.3% from its current price of $11.74. Actinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Dividend Strength: Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals does not currently pay a dividend. Actinium Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Actinium Pharmaceuticals (NYSE:ATNM)

In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock. Only 1.50% of the stock of Actinium Pharmaceuticals is held by insiders.

Earnings and Valuation of Actinium Pharmaceuticals (NYSE:ATNM

Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.81) per share. The P/E ratio of Actinium Pharmaceuticals is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Actinium Pharmaceuticals is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Actinium Pharmaceuticals has a P/B Ratio of 11.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here